Tuesday, November 17, 2026
RSS


← All Stories

Pharmaceutical

Neurocrine Biosciences (NBIX) Faces Regulatory Scrutiny After Safety Concerns: What Investors Should Know

Neurocrine Biosciences (NBIX) faces scrutiny from regulators following safety alarms, including seven patient deaths. Here's what traders ne…

Aug 12, 2026
Pharmaceutical

Definium Therapeutics (DFTX) Phase 3 Trial Success: A Potential Game Changer for Anxiety Treatment

Definium Therapeutics' successful Phase 3 trial results could reshape anxiety treatment and boost investor sentiment.

Aug 12, 2026
Pharmaceutical

Definium Therapeutics Soars on Trial Success: What This Means for Investors

Definium Therapeutics stock surged 20% following positive Phase 3 trial results, signaling a significant de-risking event for investors.

Aug 12, 2026
Pharmaceutical

Regulatory Concerns Hit Neurocrine Biosciences: A Closer Look at NBIX's Safety Woes

Neurocrine Biosciences faces scrutiny after seven patient deaths linked to its drug raise regulatory alarm bells.

Aug 12, 2026
Pharmaceutical

AbCellera's ABCL635: Positive Data Fuels Market Optimism and Analyst Upgrades

AbCellera Biologics' positive Phase 2 results for ABCL635 have led to increased analyst confidence and price target adjustments.

Aug 11, 2026
Pharmaceutical

Replimune's FDA Approval: A New Chapter for Melanoma Treatment and Investment

Replimune secures FDA accelerated approval for TUDRIQEV, a significant milestone for melanoma treatment and investor interest.

Aug 11, 2026
Pharmaceutical

PDS Biotech Shifts Focus to PDS0301: Implications for Investors

PDS Biotech's strategic pivot towards PDS0301 raises intriguing questions for investors.

Aug 11, 2026
Pharmaceutical

Amneal Pharmaceuticals Strengthens Market Position with Kashiv BioSciences Acquisition

Amneal's acquisition of Kashiv BioSciences positions it as a leader in the biosimilars market, enhancing its R&D and commercialization capab…

Aug 10, 2026
Pharmaceutical

Jazz Pharmaceuticals Expands Pipeline with $1.32 Billion Acquisition of Actio Biosciences

Jazz Pharmaceuticals announces $1.32 billion acquisition of Actio Biosciences, enhancing its rare disease pipeline.

Aug 10, 2026
Pharmaceutical

AbCellera Biologics Stock Soars on Positive Phase 2 Trial Results

AbCellera's shares surged 30.3% after positive Phase 2 trial results for its innovative antibody, ABCL635.

Aug 10, 2026
Pharmaceutical

Amneal Pharmaceuticals' Strategic Move: Acquisition of Kashiv BioSciences

Amneal's acquisition of Kashiv BioSciences positions it as a leader in the biosimilars market, indicating potential revenue growth.

Aug 10, 2026
Pharmaceutical

Jazz Pharmaceuticals' $1.32B Acquisition: What Investors Need to Know

Jazz Pharmaceuticals is set to acquire Actio Biosciences for $1.32 billion, a move that could reshape its market position.

Aug 10, 2026